2.9.21 - Cleveland Diagnostics, Inc. Raises Over $19 Million in Financing
1.13.21 - Publication of a Health Economic Analysis Demonstrates IsoPSA® Significantly Reduces Unnecessary Prostate Cancer Biopsies and Costs
10.16.19 - Cleveland Diagnostics Announces FDA Breakthrough Device Designation for Novel Prostate Cancer Diagnostic Test
5.7.19 - Cleveland Diagnostics Announces Publication of Multicenter IsoPSA Clinical Validation Study Demonstrating Improved Accuracy Over Prostate-Specific Antigen Test
5.15.17 - Cleveland Diagnostics Announces Preliminary Results from Multicenter IsoPSA™ Study Demonstrating Significantly Improved Accuracy Over Standard Prostate-Specific Antigen (PSA) Test
